Browse diseases

… improved CNS progression-free-survival and overall survival in lung cancer patients with brain metastases. More work is needed to further …

…tterns (defined as uptake <50% of maximum). In one patient with NSCLC, baseline PET showed necrotic LV segments that exhibited elevat…

… Patient 1 had repeat EUS guided FNA which again showed chronic pancreatitis then ultimately underwent a Whipple procedure due to interval i…

…arrett’s esophagus. Proteomap and enrichment analysis comparing Barrett’s esophagus progressors to non-progressors…

…xture.9–11 Methods CD8 immunohistochemistry was performed on 35 NSCLC whole-slide resection specimens and a corresponding TMA compris…

…e JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023 Nov 2;389(18):1672–1684.Cascone T, Awad MM,…

…i A, Ahmadi M, Logue S, Orive G, Pecic S, Gordon JW, Ghavami S. Rhabdomyosarcoma: current therapy, challenges, and future approaches to treatmen…

…lunteers. Animal experiments related to CAR-NK cell therapy for hepatocellular carcinoma were approved by the Institutional Animal Care and Use Committe…

…d in the clinic to markedly enhance adoptive T cell therapy for solid tumors.Acknowledgments C.H.P., I.S., Y.L., M.N.P., and J.D.P. are empl…

…p<0.001 (n=3)Abstract 359 Figure 2Tumor-trained splenocytes reg melanoma growth. (A) Low burden: B16 (1×104) + trained splenocytes (1×10…

… potential in hematologic malignancies and melanoma, but not in epithelial cancers, the most common malignancy type. Here, we report ongoing compl…

…ollowing CAR-T therapy in patients with leukemia, lymphoma, and myeloma.Methods MEDLINE, Embase, Web of Science, and Cochrane CENTRAL d…